Skip to content
My WebMD Sign In, Sign Up

Lung Cancer Health Center

Font Size

Stage II NSCLC Treatment

Standard Treatment Options for Stage II NSCLC

Standard treatment options for stage II NSCLC include the following:

Recommended Related to Lung Cancer

Lung Cancer Resources

The National Comprehensive Cancer Network is a nonprofit alliance of 21 cancer centers throughout the U.S. that treat all cancers. National Comprehensive Cancer Network  

Read the Lung Cancer Resources article > >

  1. Surgery.
  2. Neoadjuvant chemotherapy.
  3. Adjuvant chemotherapy.
  4. Radiation therapy.

Surgery

Surgery is the treatment of choice for patients with stage II NSCLC. A lobectomy, pneumonectomy, or segmental resection, wedge resection, or sleeve resection may be performed as appropriate. Careful preoperative assessment of the patient's overall medical condition, especially the patient's pulmonary reserve, is critical in considering the benefits of surgery.

Prognosis:

Despite the immediate and age-related postoperative mortality rate, a 5% to 8% mortality rate with pneumonectomy or a 3% to 5% mortality rate with lobectomy can be expected.

Evidence:

  1. The Cochrane Collaboration group reviewed 11 randomized trials with a total of 1,910 patients who underwent surgical interventions for early-stage (I-IIIA) lung cancer.[1] A pooled analysis of three trials reported the following:
    1. Four-year survival was superior in patients with resectable stage I, II, or IIIA NSCLC who underwent resection and complete ipsilateral mediastinal lymph node dissection (CMLND) compared with those who underwent resection and lymph node sampling; the hazard ratio (HR) was estimated to be 0.78 (95% confidence interval [CI], 0.65-0.93; P = .005).[1][Level of evidence: 1iiA]
    2. There was a significant reduction in any cancer recurrence (local or distant) in the CMLND group (relative risk [RR] = 0.79; 95% CI, 0.66-0.95; P = .01) that appeared mainly as the result of a reduction in the number of distant recurrences (RR = 0.78; 95% CI, 0.61-1.00; P = .05).
    3. There was no difference in operative mortality.
    4. Air leak lasting more than 5 days was significantly more common in patients assigned to CMLND (RR = 2.94; 95% CI, 1.01-8.54; P = .05).
  2. Current evidence suggests that lung cancer resection combined with CMLND is associated with a small-to-modest improvement in survival compared with lung cancer resection combined with systematic sampling of mediastinal nodes in patients with stage I, II, or IIIA NSCLC.[1][Level of evidence: 1iiA]
  3. CMLND versus lymph node sampling was evaluated in a large randomized phase III trial (ACOSOG-Z0030).[2]
    1. Preliminary analyses of operative morbidity and mortality showed comparable rates from the procedures.[2]

Limitations of evidence:

Conclusions about the efficacy of surgery for patients with local and locoregional NSCLC are limited by the small number of participants studied to date and potential methodological weaknesses of the trials.

Neoadjuvant chemotherapy

The role of chemotherapy prior to surgery was tested in clinical trials. The proposed benefits of preoperative chemotherapy include the following:

  • A reduction in tumor size that may facilitate surgical resection.
  • Early eradication of micrometastases.
  • Better tolerability.

Preoperative chemotherapy may, however, delay potentially curative surgery.

Evidence:

  1. The Cochrane Collaboration Review group reported a systematic review and meta-analysis of seven randomized controlled trials that included 988 patients and evaluated the addition of preoperative chemotherapy to surgery versus surgery alone. These trials evaluated patients with stages I, II, and IIIA NSCLC.[3]
    1. Preoperative chemotherapy provided an absolute benefit in survival of 6% across all stages of disease from 14% to 20% at 5 years (HR = 0.82; 95% CI, 0.69-0.97; P = .022).[3][Level of evidence: 1iiA]
    2. This analysis was unable to address questions such as whether particular types of patients may benefit more or less from preoperative chemotherapy.
  2. In the largest trial reported to date, 519 patients were randomly assigned to receive either surgery alone or three cycles of platinum-based chemotherapy followed by surgery. Most patients (61%) had clinical stage I disease; 31% had stage II disease; and 7% had stage III disease.[4]
    1. No survival advantage was seen.[4]
    2. Postoperative complications were similar between groups, and no impairment of quality of life was observed.
    3. There was no evidence of a benefit in terms of overall survival (OS) (HR = 1.02; 95% CI, 0.80-1.31; P = .86).
    4. Updating the systematic review by addition of the present result suggests a 12% relative survival benefit with the addition of neoadjuvant (preoperative) chemotherapy (1,507 patients; HR = 0.88; 95% CI, 0.76-1.01; P = .07), equivalent to an absolute improvement in survival of 5% at 5 years.
1|2|3|4

WebMD Public Information from the National Cancer Institute

Last Updated: May 16, 2012
This information is not intended to replace the advice of a doctor. Healthwise disclaims any liability for the decisions you make based on this information.

Today on WebMD

lung cancer overview slideshow
SLIDESHOW
what is your cancer risk
HEALTH CHECK
 
Using GPS to Detect Lung Cancer
VIDEO
mans hand putting out cigarette
Article
 
15 Cancer Symptoms Men Ignore
FEATURE
Lung Cancer Risks Myths and Facts
SLIDESHOW
 
cancer fighting foods
SLIDESHOW
Improving Lung Cancer Survival Targeted Therapy
VIDEO
 
Lung Cancer Surprising Differences Between Sexes
VIDEO
Pets Improve Your Health
SLIDESHOW
 
Vitamin D
SLIDESHOW
Lung Cancer Surgery Options
VIDEO
 

WebMD Special Sections